IM Cannabis Posts 548% Bigger Loss Despite Revenue Rise

IM Cannabis reported disappointing fiscal 2025 Q4 results, with the company posting a net loss that expanded significantly year-over-year, despite a double-digit revenue increase. The company’s losses widened sharply, underperforming expectations and signaling continued financial stress. Management provided cautious guidance for 2026, focusing on cost optimization and growth in high-margin segments, but no earnings targets were offered amid ongoing sector volatility.

Revenue

IM Cannabis generated total revenue of $15.68 million in 2025 Q4, representing a 17.6% increase compared to $13.34 million in the same period of 2024. This marks a positive trend in top-line growth despite the broader operational and market challenges the company is currently navigating.

Earnings/Net Income

The company's financial performance deteriorated significantly in the quarter, with its net loss surging to $-7.87 million, a 548.5% increase from the $-1.21 million loss in 2024 Q4. On a per-share basis, the loss widened to $1.29 from $0.33, representing a 295.2% increase in the deficit. These results underscore the continued financial pressure the company is under, as it struggles to achieve profitability despite revenue growth. The EPS performance is clearly negative and indicates worsening operational efficiency.

Price Action

IM Cannabis shares have continued to fall, with the stock price plummeting 21.33% in the latest trading day, 36.92% over the most recent full trading week, and 43.49% month-to-date. The persistent downward trend reflects investor concerns regarding the company’s financial health and future prospects.

Post-Earnings Price Action Review

The strategy of buying IM Cannabis shares following a revenue decline in the earnings report and holding them for 30 days has proven highly unprofitable. Over the past three years, this approach delivered a -99.56% return, significantly underperforming the benchmark by 142.14%. With a Sharpe ratio of -0.53 and a maximum drawdown of 99.60%, the strategy highlights the high risk and substantial potential losses associated with investing in IM Cannabis at a time of deteriorating earnings.

CEO Commentary

The CEO of IM Cannabis emphasized that the Q4 2025 results reflect ongoing challenges in market dynamics and operational scaling. Despite these difficulties, the company is making progress in cost optimization and product diversification. Strategic priorities for the company include accelerating R&D investments to strengthen its market positioning in high-margin segments, as well as expanding distribution channels to enhance its market share. Management expressed a cautious yet committed outlook, recognizing the need for disciplined execution to navigate competitive pressures while maintaining long-term value creation.

Guidance

For 2026, the company expects revenue growth of 8-10% year-over-year, with a focus on margin expansion through operational efficiency. Capital expenditures are projected to be between $15-18 million, with an emphasis on automation and facility upgrades. The CEO also highlighted qualitative goals such as strengthening regulatory compliance and exploring strategic partnerships to drive innovation. However, no specific EPS targets were provided due to the ongoing volatility in the sector.

Additional News

IM Cannabis reported 2025 total revenue of $54.7 million, a 1% increase year-over-year. Strong gains in Germany partially offset declines in Israel. Despite the modest revenue growth, the company reported a net loss of $11.8 million, consistent with the previous year. The company also highlighted ongoing liquidity risks and the threat of going concern, as it continues to face negative cash flows and high liquidity challenges. The management emphasized the need for continued cost discipline and strategic initiatives to address these financial concerns.